PL BioScience GmbH

About PL BioScience GmbH

PL BioScience GmbH's revolutionary ELAREM™ Human Platelet Lysate (HPL) platform represents a significant leap forward in regenerative medicine and advanced therapy. Built on proprietary extraction and optimization technology, ELAREM™ delivers xeno-free, naturally rich growth factors that power the expansion of stem cells, immune cells, and other therapeutically relevant cell types — outperforming Fetal Bovine Serum where it matters most: in consistency, ethics, and clinical readiness. From first-in-vitro studies through GMP-manufacturing of advanced therapy medicinal products (ATMPs), our platform enables seamless transitions from blood bank to bedside. Since our founding in 2015, PL BioScience has been at the forefront of animal-suffering-free cell culture solutions for regenerative medicine and advanced therapy. What began as a mission to provide reliable xeno-free supplements has evolved into a comprehensive portfolio of Research-grade and GMP-grade ELAREM™ products — supporting academic labs, CDMOs, and biotech companies developing cell therapies and tissue-engineered constructs. Today, our global customers rely on ELAREM™ for the batch-to-batch consistency, premium quality, and ethical sourcing that their regulatory pathways demand. At PL BioScience, we will continue to evolve alongside the regenerative medicine and advanced therapy industry — providing a dependable, transparent partnership that empowers developers to bring life-changing treatments to patients faster. With products designed for scalability, clinical performance, and regulatory readiness, ELAREM™ is more than an alternative to FBS. It's the standard for the next generation of cell-based therapies. Join us in transforming regenerative medicine!